Abstract
Diffuse intrinsic pontine gliomas (DIPGs) are incurable childhood brain tumors, whereby the standard of care is focal radiation, a treatment that provides temporary relief for most patients. Surprisingly, decades of clinical trials have failed to identify additional therapies that can prolong survival in this disease. In this conference manuscript, we discuss how genetic engineered mouse modeling techniques with the use of a retroviral gene delivery system can help dissect the complex pathophysiology of this disease. With this approach, autochthonous murine DIPG models can be readily induced to (1) help interrogate the function of novel genetic alterations in tumorigenesis, (2) identify candidate cells of origin for this disease, (3) address how region-specific differences in the central nervous system influence the process of gliomagenesis, and (4) evaluate novel therapeutics in an immunocompetent model.
Highlights
TO DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)Pediatric brain tumors are the leading cause of cancer-related death in children [1]
This publication associated with the Alicia Pueyo DIPG workshop that was held in Barcelona on March 12–13, 2018 will review efforts to better understand the pathogenesis of DIPG using genetic mouse modeling techniques
We successfully developed a genetic model of DIPG using the RCAS/tumor virus A (TVA) modeling system by expressing a potent glioma driver, platelet-derived growth factor-B (PDGF-B), in the brainstem [6, 24]
Summary
Decades of clinical trials have failed to identify additional therapies that can prolong survival in this disease. In this conference manuscript, we discuss how genetic engineered mouse modeling techniques with the use of a retroviral gene delivery system can help dissect the complex pathophysiology of this disease. We discuss how genetic engineered mouse modeling techniques with the use of a retroviral gene delivery system can help dissect the complex pathophysiology of this disease With this approach, autochthonous murine DIPG models can be readily induced to [1] help interrogate the function of novel genetic alterations in tumorigenesis, [2] identify candidate cells of origin for this disease, [3] address how region-specific differences in the central nervous system influence the process of gliomagenesis, and [4] evaluate novel therapeutics in an immunocompetent model
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
